Genmab A/S (GMAB) Competitors

$26.87 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$26.80 -0.07 (-0.25%)

As of 05/22/2026 07:55 PM Eastern

GMAB vs. TAK, ARGX, TEVA, ONC, and RVMD

Should you buy Genmab A/S stock or one of its competitors? MarketBeat compares Genmab A/S with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genmab A/S include Takeda Pharmaceutical (TAK), argenex (ARGX), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

How does Genmab A/S compare to Takeda Pharmaceutical?

Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Genmab A/S has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.50	$963M	$1.32	20.36
Takeda Pharmaceutical	$28.32B	1.82	$1.27B	$0.39	41.60

Genmab A/S has a net margin of 21.05% compared to Takeda Pharmaceutical's net margin of 4.31%. Genmab A/S's return on equity of 15.34% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

Genmab A/S currently has a consensus price target of $39.07, indicating a potential upside of 45.41%. Given Genmab A/S's stronger consensus rating and higher possible upside, research analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Genmab A/S and Genmab A/S both had 1 articles in the media. Genmab A/S's average media sentiment score of 0.00 beat Takeda Pharmaceutical's score of -0.36 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Genmab A/S beats Takeda Pharmaceutical on 12 of the 16 factors compared between the two stocks.

How does Genmab A/S compare to argenex?

Genmab A/S (NASDAQ:GMAB) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

argenex has a net margin of 31.31% compared to Genmab A/S's net margin of 21.05%. argenex's return on equity of 33.28% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
argenex	31.31%	33.28%	28.16%

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, argenex had 1 more articles in the media than Genmab A/S. MarketBeat recorded 2 mentions for argenex and 1 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.00 equaled argenex'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S presently has a consensus target price of $39.07, suggesting a potential upside of 45.41%. argenex has a consensus target price of $1,017.78, suggesting a potential upside of 26.20%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

argenex has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.50	$963M	$1.32	20.36
argenex	$4.25B	11.75	$1.29B	$22.46	35.91

Genmab A/S has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Summary

argenex beats Genmab A/S on 13 of the 15 factors compared between the two stocks.

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Genmab A/S (NASDAQ:GMAB) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Genmab A/S has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 1 mentions for Genmab A/S. Teva Pharmaceutical Industries' average media sentiment score of 0.99 beat Genmab A/S's score of 0.00 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	10 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 21.05% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Teva Pharmaceutical Industries has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.50	$963M	$1.32	20.36
Teva Pharmaceutical Industries	$17.26B	2.27	$1.41B	$1.33	25.59

Genmab A/S currently has a consensus price target of $39.07, indicating a potential upside of 45.41%. Teva Pharmaceutical Industries has a consensus price target of $41.78, indicating a potential upside of 22.75%. Given Genmab A/S's stronger consensus rating and higher probable upside, research analysts clearly believe Genmab A/S is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Teva Pharmaceutical Industries beats Genmab A/S on 9 of the 16 factors compared between the two stocks.

How does Genmab A/S compare to BeOne Medicines?

Genmab A/S (NASDAQ:GMAB) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Genmab A/S currently has a consensus price target of $39.07, indicating a potential upside of 45.41%. BeOne Medicines has a consensus price target of $389.15, indicating a potential upside of 25.43%. Given Genmab A/S's stronger consensus rating and higher probable upside, research analysts plainly believe Genmab A/S is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

Genmab A/S has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Genmab A/S has higher earnings, but lower revenue than BeOne Medicines. Genmab A/S is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.50	$963M	$1.32	20.36
BeOne Medicines	$5.34B	6.37	$286.93M	$4.47	69.41

In the previous week, BeOne Medicines had 3 more articles in the media than Genmab A/S. MarketBeat recorded 4 mentions for BeOne Medicines and 1 mentions for Genmab A/S. BeOne Medicines' average media sentiment score of 0.48 beat Genmab A/S's score of 0.00 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S has a net margin of 21.05% compared to BeOne Medicines' net margin of 8.94%. Genmab A/S's return on equity of 15.34% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
BeOne Medicines	8.94%	12.06%	6.69%

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BeOne Medicines beats Genmab A/S on 9 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to Revolution Medicines?

Genmab A/S (NASDAQ:GMAB) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Genmab A/S has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

In the previous week, Revolution Medicines had 8 more articles in the media than Genmab A/S. MarketBeat recorded 9 mentions for Revolution Medicines and 1 mentions for Genmab A/S. Revolution Medicines' average media sentiment score of 1.16 beat Genmab A/S's score of 0.00 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 8.2% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Genmab A/S has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.50	$963M	$1.32	20.36
Revolution Medicines	$11.58M	2,782.53	-$1.13B	-$7.07	N/A

Genmab A/S has a net margin of 21.05% compared to Revolution Medicines' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Revolution Medicines	N/A	-83.22%	-59.06%

Genmab A/S currently has a consensus target price of $39.07, suggesting a potential upside of 45.41%. Revolution Medicines has a consensus target price of $111.35, suggesting a potential downside of 26.53%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Revolution Medicines beats Genmab A/S on 9 of the 17 factors compared between the two stocks.

Get Genmab A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMAB vs. The Competition

Export

Metric	Genmab A/S	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.75B	$3.37B	$6.45B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	20.36	18.74	21.22	25.65
Price / Sales	4.50	323.98	553.92	86.28
Price / Cash	16.69	125.17	43.49	56.67
Price / Book	2.95	7.09	10.37	7.14
Net Income	$963M	$24.45M	$3.57B	$335.98M
7 Day Performance	1.90%	5.45%	6.01%	3.56%
1 Month Performance	N/A	2.43%	3.52%	2.54%
1 Year Performance	29.12%	62.98%	34.13%	35.05%

Genmab A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
GMAB Genmab A/S	3.8584 of 5 stars	$26.87 flat	$39.07 +45.4%	+29.1%	$16.75B	$3.72B	20.36	3,029
TAK Takeda Pharmaceutical	2.1799 of 5 stars	$16.58 -0.2%	N/A	+11.3%	$52.86B	$28.32B	42.50	47,455
ARGX argenex	4.3144 of 5 stars	$776.26 -2.9%	$1,017.78 +31.1%	+37.2%	$49.46B	$4.25B	34.56	1,863
TEVA Teva Pharmaceutical Industries	4.6109 of 5 stars	$34.08 -0.6%	$41.78 +22.6%	+100.9%	$39.43B	$17.26B	25.62	33,950
ONC BeOne Medicines	4.1624 of 5 stars	$293.09 -0.1%	$389.15 +32.8%	+28.5%	$32.18B	$5.34B	65.57	12,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMAB) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genmab A/S (GMAB) Competitors

GMAB vs. TAK, ARGX, TEVA, ONC, and RVMD

How does Genmab A/S compare to Takeda Pharmaceutical?

Summary

How does Genmab A/S compare to argenex?

Summary

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Summary

How does Genmab A/S compare to BeOne Medicines?

Summary

How does Genmab A/S compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMAB vs. The Competition

Genmab A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genmab A/S (GMAB) Competitors

GMAB vs. TAK, ARGX, TEVA, ONC, and RVMD

How does Genmab A/S compare to Takeda Pharmaceutical?

Which has more volatility and risk, GMAB or TAK?

Which has better earnings and valuation, GMAB or TAK?

Is GMAB or TAK more profitable?

Do analysts rate GMAB or TAK?

Do institutionals & insiders have more ownership in GMAB or TAK?

Does the media refer more to GMAB or TAK?

Summary

How does Genmab A/S compare to argenex?

Is GMAB or ARGX more profitable?

Do institutionals and insiders hold more shares of GMAB or ARGX?

Does the media favor GMAB or ARGX?

Do analysts recommend GMAB or ARGX?

Which has better valuation and earnings, GMAB or ARGX?

Which has more volatility & risk, GMAB or ARGX?

Summary

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Which has more volatility and risk, GMAB or TEVA?

Does the media prefer GMAB or TEVA?

Is GMAB or TEVA more profitable?

Which has stronger earnings & valuation, GMAB or TEVA?

Do analysts recommend GMAB or TEVA?

Do institutionals & insiders believe in GMAB or TEVA?

Summary

How does Genmab A/S compare to BeOne Medicines?

Do analysts prefer GMAB or ONC?

Which has more volatility & risk, GMAB or ONC?

Which has higher valuation and earnings, GMAB or ONC?

Does the media prefer GMAB or ONC?

Is GMAB or ONC more profitable?

Do institutionals & insiders believe in GMAB or ONC?

Summary

How does Genmab A/S compare to Revolution Medicines?

Which has more risk and volatility, GMAB or RVMD?

Does the media refer more to GMAB or RVMD?

Do institutionals & insiders hold more shares of GMAB or RVMD?

Which has better earnings and valuation, GMAB or RVMD?

Is GMAB or RVMD more profitable?

Do analysts recommend GMAB or RVMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMAB vs. The Competition

Genmab A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools